Daniel P. Nadeau
GlaxoSmithKline
9 Papers
59 Citations
Daniel P. Nadeau is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Apoptosis & Caspase. The author has an hindex of 9, co-authored 9 publications.
Chat about Author
Papers
Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality.
Dennis Lee,Scott A. Long,Jerry L. Adams,George K. Chan,Kalindi Vaidya,Terry A. Francis,Kristine Kikly,James D. Winkler,Chiu-Mei Sung,Christine Debouck,Susan B. Richardson,Mark Alan Levy,Walter E. DeWolf,Paul M. Keller,Thaddeus A. Tomaszek,Martha S. Head,Ryan M Dominic,R. Curtis Haltiwanger,Po-Huang Liang,Cheryl A. Janson,Patrick McDevitt,Kyung O. Johanson,Nestor O. Concha,Winnie Chan,Sherin S. Abdel-Meguid,Alison M. Badger,Michael W. Lark,Daniel P. Nadeau,Larry J. Suva,Maxine Gowen,Mark E. Nuttall +30 more
TL;DR: The inhibition of apoptosis and maintenance of cell functionality with a caspase 3/7-selective inhibitor is demonstrated for the first time, and suggests that targeting these two caspases alone is sufficient for blocking apoptosis.
250
Idoxifene: A Novel Selective Estrogen Receptor Modulator Prevents Bone Loss and Lowers Cholesterol Levels in Ovariectomized Rats and Decreases Uterine Weight in Intact Rats
Mark Nuttall,Bradbeer Jeremy N,George B. Stroup,Daniel P. Nadeau,Sandra J. Hoffman,Hugh Zhao,Sabine Rehm,Maxine Gowen +7 more
TL;DR: Molecular-based evidence is provided to support the observations in vivo of a novel selective estrogen receptor modulator (SERM) mechanism of action in bone and endometrial cells and suggest that idoxifene may be effective in the prevention of osteoporosis and other postmenopausal diseases without producing unwanted estrogenic effects on the endometrium.
Inhibition of caspase‐3‐like activity prevents apoptosis while retaining functionality of human chondrocytes in vitro
Mark E. Nuttall,Daniel P. Nadeau,Paul W. Fisher,Fei-Lan Wang,Paul M. Keller,Walter E. DeWolf,Mary B. Goldring,Alison M. Badger,Dennis Lee,Mark Alan Levy,Maxine Gowen,Michael W. Lark +11 more
TL;DR: The prevention of apoptosis by caspase‐3 inhibition was sufficient to maintain cell functionality as assessed by the retention of type‐II collagen promoter activity.
89
Identification and cloning of a human urea transporter HUT11, which is downregulated during adipogenesis of explant cultures of human bone.
William P. Prichett,A.J Patton,John A. Field,Kimberly A. Brun,John G. Emery,K.B. Tan,David J. Rieman,Heather A. McClung,Daniel P. Nadeau,Jeffrey L. Mooney,Larry J. Suva,Maxine Gowen,Mark E. Nuttall +12 more
TL;DR: Cl cloning and sequencing of the human urea transporter HUT11 are reported from primary human osteoblasts and tissue distribution for the bone explant‐derived form of HUT 11 mRNA is reported and a reciprocal relationship between the expression of H UT11 and the nuclear hormone receptor peroxisome proliferator‐activated receptor gamma 2, which is a marker of adipocyte differentiation is shown.
21
Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents.
Mark E. Nuttall,Israil Pendrak,John G. Emery,Daniel P. Nadeau,Paul W. Fisher,Thema A. Nicholson,Yuan Zhu,Larry J. Suva,William Dennis Kingsbury,Maxine Gowen +9 more
TL;DR: The ability of these analogues of ICI 182,780 to inhibit oestrogen-stimulated transcriptional activity and cell proliferation suggests that these agents, in particular the sulphone analogue, have therapeutic potential in the treatment of breast cancer without exhibiting the unwanted Oestrogenic effects in the endometrium.
20